These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6372 related articles for article (PubMed ID: 2492121)

  • 21. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive cellular immunotherapy to the endometrial carcinoma cell line xenografts in nude mice.
    Shimizu H; Inoue M; Tanizawa O
    Gynecol Oncol; 1989 Aug; 34(2):195-9. PubMed ID: 2787771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
    Manning LS; Bowman RV; Darby SB; Robinson BW
    Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target cell membrane modification and susceptibility to lymphokine activated killer cell mediated lysis. I. Trinitrophenyl has no effect on murine normal cells and tumors.
    Lefor AT
    J Surg Res; 1991 Oct; 51(4):316-23. PubMed ID: 1921371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.
    Saijo N; Ozaki A; Sakurai M; Ishihara J; Takahashi H; Sasaki Y; Hoshi A; Hamburger AW
    Jpn J Cancer Res; 1986 May; 77(5):487-93. PubMed ID: 3089980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.
    Okuno K; Takagi H; Nakamura T; Nakamura Y; Iwasa Z; Yasutomi M
    Cancer; 1986 Sep; 58(5):1001-6. PubMed ID: 2425926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
    Morita T; Yonese Y; Minato N
    J Natl Cancer Inst; 1987 Mar; 78(3):441-50. PubMed ID: 3102826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [LAK sensitivity of human pancreas carcinoma cell lines].
    Sugiura H
    Hokkaido Igaku Zasshi; 1993 Nov; 68(6):921-34. PubMed ID: 7906667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE; Vujanovic NL; Hiserodt JC
    Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells.
    Wang P; Yu JP; Gao SY; An XM; Ren XB; Wang XG; Li WL
    Cell Immunol; 2008; 253(1-2):59-65. PubMed ID: 18522858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
    Chen QK; Yuan SZ
    Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):353-5. PubMed ID: 7895586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.
    Shimizu K; Okamoto Y; Miyao Y; Yamada M; Ushio Y; Hayakawa T; Ikeda H; Mogami H
    J Neurosurg; 1987 Apr; 66(4):519-21. PubMed ID: 3494108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 319.